검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | everolimus |
Overview Company | SCRI Development Innovations, LLC |
Overview Modality | ADC |
Overview Target | Renal Cell Carcinoma |
Overview Indication | Intracranial Meningioma |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarker for treatment efficacy |
PK/PD Half-life | 30 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Markedly elevated blood concentrations of everolimus during concomitant posaconazole therapy in a liver transplant recipient: a case report.. Everolimus (EVL) is widely used as an immunosuppressive agent in combination with calcineurin inhibitors, including tacrolimus (TAC), after liver transplantation. Posaconazole (PSCZ) is a triazole antifungal agent used for the treatment and prophylaxis of in… |
Clinical Primary efficacy | ORR 78.4% |
Clinical ORR | 78.4% |
Clinical Result source | ClinicalTrials.gov NCT01088048 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | everolimus |
Overview Company | SCRI Development Innovations, LLC |
Overview Modality | ADC |
Overview Target | Renal Cell Carcinoma |
Overview Indication | Intracranial Meningioma |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarker for treatment efficacy |
PK/PD Half-life | 30 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Markedly elevated blood concentrations of everolimus during concomitant posaconazole therapy in a liver transplant recipient: a case report.. Everolimus (EVL) is widely used as an immunosuppressive agent in combination with calcineurin inhibitors, including tacrolimus (TAC), after liver transplantation. Posaconazole (PSCZ) is a triazole antifungal agent used for the treatment and prophylaxis of in… |
Clinical Primary efficacy | ORR 78.4% |
Clinical ORR | 78.4% |
Clinical Result source | ClinicalTrials.gov NCT01088048 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교